tiprankstipranks
Halozyme Therapeutics (HALO)
NASDAQ:HALO
US Market
HALO
Halozyme
RESEARCH TOOLSreports
Want to see HALO full AI Analyst Report?

Halozyme (HALO) Stock Forecast & Price Target

1,178 Followers
See the Price Targets and Ratings of:

HALO Analyst Ratings

Strong Buy
5Ratings
Strong Buy
4 Buy
1 Hold
0 Sell
Based on 5 analysts giving stock ratings to
Halozyme
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

HALO Stock 12 Month Forecast

Average Price Target

$89.40
▲(29.02% Upside)
Based on 5 Wall Street analysts offering 12 month price targets for Halozyme in the last 3 months. The average price target is $89.40 with a high forecast of $96.00 and a low forecast of $75.00. The average price target represents a 29.02% change from the last price of $69.29.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"51":"$51","74":"$74","97":"$97","62.5":"$62.5","85.5":"$85.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":96,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$96.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":89.4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$89.40</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$75.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[51,62.5,74,85.5,97],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2025","6":"Oct<br/>2025","9":"Jan<br/>2026","12":"Apr<br/>2026","25":"Apr<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,65.4,67.75384615384615,70.10769230769232,72.46153846153847,74.81538461538462,77.16923076923078,79.52307692307693,81.87692307692308,84.23076923076923,86.58461538461539,88.93846153846154,91.2923076923077,93.64615384615385,{"y":96,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,65.4,67.24615384615385,69.0923076923077,70.93846153846154,72.78461538461539,74.63076923076923,76.47692307692309,78.32307692307693,80.16923076923078,82.01538461538462,83.86153846153847,85.70769230769231,87.55384615384617,{"y":89.4,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,65.4,66.13846153846154,66.87692307692308,67.61538461538461,68.35384615384616,69.0923076923077,69.83076923076923,70.56923076923077,71.3076923076923,72.04615384615384,72.78461538461539,73.52307692307693,74.26153846153846,{"y":75,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":61.87,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":60.03,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":55.64,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":52.92,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":59.02,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":73.34,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":74.94,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":65.19,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68.1,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":67.3,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":74.45,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":69.85,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":65.4,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$96.00Average Price Target$89.40Lowest Price Target$75.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Morgan Stanley Analyst forecast on HALO
Sean Laaman
Morgan Stanley
Morgan Stanley
$94→$96
Buy
38.55%
Upside
Reiterated
04/21/26
Halozyme price target raised to $96 from $94 at Morgan StanleyHalozyme price target raised to $96 from $94 at Morgan Stanley
TD Cowen Analyst forecast on HALO
Brendan Smith
TD Cowen
TD Cowen
$96
Buy
38.55%
Upside
Reiterated
04/09/26
Halozyme: Underappreciated, Durable Royalty-Driven Growth Beyond 2028 Supports Buy Rating
H.C. Wainwright Analyst forecast on HALO
Mitchell Kapoor
H.C. Wainwright
H.C. Wainwright
$90
Buy
29.89%
Upside
Reiterated
04/07/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Wells Fargo Analyst forecast on HALO
Mohit Bansal
Wells Fargo
Wells Fargo
$65→$75
Hold
8.24%
Upside
Reiterated
02/19/26
Halozyme price target raised to $75 from $65 at Wells FargoHalozyme price target raised to $75 from $65 at Wells Fargo
Benchmark Co. Analyst forecast on HALO
Robert Wasserman
Benchmark Co.
Benchmark Co.
$75→$90
Buy
29.89%
Upside
Reiterated
02/19/26
Halozyme price target raised to $90 from $75 at BenchmarkHalozyme price target raised to $90 from $75 at Benchmark
Leerink Partners Analyst forecast on HALO
David Risinger
Leerink Partners
Leerink Partners
―
Hold
―
Reiterated
01/08/26
Analysts Offer Insights on Healthcare Companies: Climb Bio (NASDAQ: CLYM) and Halozyme (NASDAQ: HALO)
Goldman Sachs Analyst forecast on HALO
Corinne Johnson
Goldman Sachs
Goldman Sachs
$56
Sell
-19.18%
Downside
Downgraded
12/04/25
Halozyme downgraded to Sell from Neutral at Goldman SachsHalozyme downgraded to Sell from Neutral at Goldman Sachs
Citizens JMP Analyst forecast on HALO
Jason Butler
Citizens JMP
Citizens JMP
$91→$92
Buy
32.78%
Upside
Reiterated
11/04/25
Halozyme price target raised to $92 from $91 at Citizens JMPHalozyme price target raised to $92 from $91 at Citizens JMP
J.P. Morgan Analyst forecast on HALO
Jessica Fye
J.P. Morgan
J.P. Morgan
$63→$65
Hold
-6.19%
Downside
Reiterated
10/27/25
Halozyme price target raised to $65 from $63 at JPMorganHalozyme price target raised to $65 from $63 at JPMorgan
Evercore ISI Analyst forecast on HALO
Michael DiFiore
Evercore ISI
Evercore ISI
$55
Buy
-20.62%
Downside
Reiterated
05/15/25
Evercore ISI reiterates Outperform Rating on Halozyme Therapeutics (HALO)Evercore ISI analyst Michael DiFiore reiterated an Outperform rating on Halozyme Therapeutics (NASDAQ: HALO).
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Morgan Stanley Analyst forecast on HALO
Sean Laaman
Morgan Stanley
Morgan Stanley
$94→$96
Buy
38.55%
Upside
Reiterated
04/21/26
Halozyme price target raised to $96 from $94 at Morgan StanleyHalozyme price target raised to $96 from $94 at Morgan Stanley
TD Cowen Analyst forecast on HALO
Brendan Smith
TD Cowen
TD Cowen
$96
Buy
38.55%
Upside
Reiterated
04/09/26
Halozyme: Underappreciated, Durable Royalty-Driven Growth Beyond 2028 Supports Buy Rating
H.C. Wainwright Analyst forecast on HALO
Mitchell Kapoor
H.C. Wainwright
H.C. Wainwright
$90
Buy
29.89%
Upside
Reiterated
04/07/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Wells Fargo Analyst forecast on HALO
Mohit Bansal
Wells Fargo
Wells Fargo
$65→$75
Hold
8.24%
Upside
Reiterated
02/19/26
Halozyme price target raised to $75 from $65 at Wells FargoHalozyme price target raised to $75 from $65 at Wells Fargo
Benchmark Co. Analyst forecast on HALO
Robert Wasserman
Benchmark Co.
Benchmark Co.
$75→$90
Buy
29.89%
Upside
Reiterated
02/19/26
Halozyme price target raised to $90 from $75 at BenchmarkHalozyme price target raised to $90 from $75 at Benchmark
Leerink Partners Analyst forecast on HALO
David Risinger
Leerink Partners
Leerink Partners
―
Hold
―
Reiterated
01/08/26
Analysts Offer Insights on Healthcare Companies: Climb Bio (NASDAQ: CLYM) and Halozyme (NASDAQ: HALO)
Goldman Sachs Analyst forecast on HALO
Corinne Johnson
Goldman Sachs
Goldman Sachs
$56
Sell
-19.18%
Downside
Downgraded
12/04/25
Halozyme downgraded to Sell from Neutral at Goldman SachsHalozyme downgraded to Sell from Neutral at Goldman Sachs
Citizens JMP Analyst forecast on HALO
Jason Butler
Citizens JMP
Citizens JMP
$91→$92
Buy
32.78%
Upside
Reiterated
11/04/25
Halozyme price target raised to $92 from $91 at Citizens JMPHalozyme price target raised to $92 from $91 at Citizens JMP
J.P. Morgan Analyst forecast on HALO
Jessica Fye
J.P. Morgan
J.P. Morgan
$63→$65
Hold
-6.19%
Downside
Reiterated
10/27/25
Halozyme price target raised to $65 from $63 at JPMorganHalozyme price target raised to $65 from $63 at JPMorgan
Evercore ISI Analyst forecast on HALO
Michael DiFiore
Evercore ISI
Evercore ISI
$55
Buy
-20.62%
Downside
Reiterated
05/15/25
Evercore ISI reiterates Outperform Rating on Halozyme Therapeutics (HALO)Evercore ISI analyst Michael DiFiore reiterated an Outperform rating on Halozyme Therapeutics (NASDAQ: HALO).
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxx
xxx
xxx
xxx
xxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Halozyme

3 Months
xxx
Success Rate
12/17 ratings generated profit
71%
Average Return
+6.12%
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 3 Months would result in 70.59% of your transactions generating a profit, with an average return of +6.12% per trade.
1 Year
Mitchell KapoorH.C. Wainwright
Success Rate
25/30 ratings generated profit
83%
Average Return
+21.90%
Copying Mitchell Kapoor's trades and holding each position for 1 Year would result in 83.33% of your transactions generating a profit, with an average return of +21.90% per trade.
2 Years
xxx
Success Rate
25/28 ratings generated profit
89%
Average Return
+34.27%
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 2 Years would result in 89.29% of your transactions generating a profit, with an average return of +34.27% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

HALO Analyst Recommendation Trends

Rating
Dec 25
Jan 26
Feb 26
Mar 26
Apr 26
Strong Buy
0
0
0
0
0
Buy
14
14
12
10
8
Hold
3
2
2
2
1
Sell
2
1
1
0
0
Strong Sell
0
0
0
0
0
total
19
17
15
12
9
In the current month, HALO has received 8 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. HALO average Analyst price target in the past 3 months is 89.40.
Each month's total comprises the sum of three months' worth of ratings.

HALO Financial Forecast

HALO Earnings Forecast

Next quarter’s earnings estimate for HALO is $1.54 with a range of $1.42 to $1.62. The previous quarter’s EPS was -$0.24. HALO beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year HALO has Performed in-line its overall industry.
Next quarter’s earnings estimate for HALO is $1.54 with a range of $1.42 to $1.62. The previous quarter’s EPS was -$0.24. HALO beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year HALO has Performed in-line its overall industry.

HALO Sales Forecast

Next quarter’s sales forecast for HALO is $358.56M with a range of $341.82M to $377.74M. The previous quarter’s sales results were $451.77M. HALO beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year HALO has Performed in-line its overall industry.
Next quarter’s sales forecast for HALO is $358.56M with a range of $341.82M to $377.74M. The previous quarter’s sales results were $451.77M. HALO beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year HALO has Performed in-line its overall industry.

HALO Stock Forecast FAQ

What is HALO’s average 12-month price target, according to analysts?
Based on analyst ratings, Halozyme Therapeutics’s 12-month average price target is 89.40.
    What is HALO’s upside potential, based on the analysts’ average price target?
    Halozyme Therapeutics has 29.02% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is HALO a Buy, Sell or Hold?
          Halozyme Therapeutics has a consensus rating of Strong Buy which is based on 4 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Halozyme Therapeutics’s price target?
            The average price target for Halozyme Therapeutics is 89.40. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $96.00 ,the lowest forecast is $75.00. The average price target represents 29.02% Increase from the current price of $69.29.
              What do analysts say about Halozyme Therapeutics?
              Halozyme Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 5 Wall Streets Analysts.
                How can I buy shares of HALO?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.